WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

After the Hang Seng Index fell 63 points, it rose 109 points and WuXi decimated 20% https://m.hkej.com/landing/mobarticle2?id=3245272 ... Foreign sources quoted news that US President Biden is about to sign a new executive order to expand US bio-manufacturing to reduce dependence on China. The pharmaceutical outsourcing service industry (CXO) was sold out across the board this morning. ....

https://finance.sina.cn/hkstock/sckxjfx/2022-09-09/detail-imqqsmrn8424147.d.html?from=wap

WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey https://www.prnewswire.co.uk/news-releases/wuxi-biologics-announces-gmp-release-of-its-first-north-american-biomanufacturing-facility-in-cranbury-new-jersey-819520512.html

http://www.takungpao.com/finance/236135/2022/0823/756604.html Share Screening

Lyon: Maintain "Outperform" rating on WuXi Biologics (02269), target price raised to HK$84 https://finance.sina.cn/hkstock/ggpj/2022-08-22/detail-imizmscv7204955.d.html?from=wap

"Research Report" Goldman Sachs downgrades WuXi Biologics (02269.HK) earnings forecast to reflect slightly lower gross profit rating "Buy http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1206110/3

Zhongtai Securities: Maintain "Buy" rating on WuXi Biologics (02269); capacity expansion to accelerate commercialization projects is expected to continue https://hk.investing.com/news/stock-market-news/article-249098

Essence Securities: Rating WuXi Biologics (02269) "Buy-A" to Achieve High Growth in 22H1 https://finance.sina.cn/hkstock/ggpj/2022-08-19/detail-imizirav8789043.d.html?from=wap

WuXi Biologics (02269) Subsidiary WuXi XDC Granted a Total of 9,052,800 Share Options https://finance.sina.cn/hkstock/gsxw/2022-08-18/detail-imizirav8726980.d.html?from=wap

http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1205548/1

WuXi Biologics Reports Strong 2022 Interim Results https://www.prnewswire.com/news-releases/wuxi-biologics-reports-strong-2022-interim-results-301607649.html Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 Million Net Profit Grew by 39.2% Y-o-Y to RMB2,621.2 Million Adjusted Net Profit Rose by 60.9% to RMB2,914.9 Million Total Backlog Reached US$18,467 Million ...

"HSI Deepens Loss to Over 350 Pts; CN Consumers, Drugs In Sell-off; Anta, BYD, Techtronic Ind, WuXi Bio Sink Over 4-6% AASTOCKS Financial News - Latest News" http://www.aastocks.com/en/stocks/news/aafn-con/now.1203517/latest-news

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1202446/company-news/HK6

WuXi Biologics (02269) rose over 4%, reached strategic cooperation with AstraZeneca for the localized production of new crown prevention and neutralizing antibody Enshide https://finance.sina.cn/hkstock/sckxjfx/2022-08-04/detail-imizmscv4789918.d.html?from=wap

WuXi Biologics Steps into the Harvest Period, Actively Strengthens the Global... https://www.donews.com/article/detail/6337/44980.html